These findings underpinned the notion that centered on MGAT4A, p53‐mutants promote endometrial carcinoma (EC) aggressiveness through miRNAs, N‐glycosylation, and glucose metabolism. This evidence concerns the gene TP53 and endometrial carcinoma.